Filing Details

Accession Number:
0001735276-23-000009
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-14 16:03:39
Reporting Period:
2023-02-10
Accepted Time:
2023-02-14 16:03:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178670 Alnylam Pharmaceuticals Inc. ALNY Pharmaceutical Preparations (2834) 770602661
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1458494 Akshay Vaishnaw 675 West Kendall Street
Henri A. Termeer Square
Cambridge MA 02142
President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-02-10 30,913 $63.00 53,014 No 4 M Direct
Common Stock Disposition 2023-02-10 1,709 $213.13 51,305 No 4 S Direct
Common Stock Disposition 2023-02-10 2,307 $214.28 48,998 No 4 S Direct
Common Stock Disposition 2023-02-10 10,279 $215.59 38,719 No 4 S Direct
Common Stock Disposition 2023-02-10 19,447 $216.38 19,272 No 4 S Direct
Common Stock Disposition 2023-02-10 4,302 $217.05 14,970 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2023-02-10 30,913 $0.00 30,913 $63.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2023-12-18 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 515 Indirect by Managed Account
Footnotes
  1. All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022.
  2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $212.71 to $213.70. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $213.72 to $214.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $214.88 to $215.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $215.89 to $216.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  6. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $216.96 to $217.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  7. Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
  8. The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.